• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Director Jenkins George M bought $100,797 worth of shares (4,990 units at $20.20), increasing direct ownership by 1% to 183,171 units (SEC Form 4)

    4/10/25 7:06:12 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PVLA alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    JENKINS GEORGE M

    (Last) (First) (Middle)
    C/O PALVELLA THERAPEUTICS, INC.
    125 STRAFFORD AVENUE, SUITE 360

    (Street)
    WAYNE PA 19087

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    PALVELLA THERAPEUTICS, INC. [ PVLA ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    04/09/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 04/09/2025 P 2,500 A $20.13 183,171 D
    Common Stock 04/09/2025 P 2,490 A $20.27 13,516 I by foundation(1)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Eagles Mere Air Museum Foundation
    By: /s/ Kathleen A. McGowan For: George Jenkins 04/10/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PVLA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PVLA

    DatePrice TargetRatingAnalyst
    1/7/2026$205.00Outperform
    Mizuho
    12/5/2025$167.00Buy
    BTIG Research
    12/4/2025$175.00Buy
    Craig Hallum
    11/19/2025$143.00Outperform → Strong Buy
    Raymond James
    9/9/2025$85.00Outperform
    Oppenheimer
    8/6/2025$54.00Outperform
    Raymond James
    7/21/2025$56.00Buy
    Truist
    4/9/2025$50.00Buy
    Chardan Capital Markets
    More analyst ratings

    $PVLA
    SEC Filings

    View All

    Palvella Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    4/7/26 7:30:15 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Palvella Therapeutics Inc.

    10-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    3/31/26 8:30:27 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - PALVELLA THERAPEUTICS, INC. (0001583648) (Filer)

    3/31/26 8:00:11 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Jenkins George M

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    4/1/26 4:05:23 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Goin Kathleen

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    3/20/26 4:05:15 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jenkins George M bought $500,000 worth of shares (4,000 units at $125.00), increasing direct ownership by 2% to 187,171 units (SEC Form 4)

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    3/2/26 8:00:54 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $PVLA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Director Jenkins George M bought $500,000 worth of shares (4,000 units at $125.00), increasing direct ownership by 2% to 187,171 units (SEC Form 4)

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    3/2/26 8:00:54 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Heron Elaine J bought $300,000 worth of shares (2,400 units at $125.00), increasing direct ownership by 5% to 47,812 units (SEC Form 4)

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    3/2/26 8:00:10 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jenkins George M bought $100,797 worth of shares (4,990 units at $20.20), increasing direct ownership by 1% to 183,171 units (SEC Form 4)

    4 - PALVELLA THERAPEUTICS, INC. (0001583648) (Issuer)

    4/10/25 7:06:12 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mizuho initiated coverage on Palvella Therapeutics with a new price target

    Mizuho initiated coverage of Palvella Therapeutics with a rating of Outperform and set a new price target of $205.00

    1/7/26 9:14:06 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on Palvella Therapeutics with a new price target

    BTIG Research initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $167.00

    12/5/25 8:40:54 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Craig Hallum initiated coverage on Palvella Therapeutics with a new price target

    Craig Hallum initiated coverage of Palvella Therapeutics with a rating of Buy and set a new price target of $175.00

    12/4/25 8:47:32 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Financials

    Live finance-specific insights

    View All

    Palvella Therapeutics to Host Full Year 2025 Financial Results Conference Call and Provide a Corporate Update on March 31, 2026

    WAYNE, Pa., March 24, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. ("Palvella" or "the Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that the Company will report its full year 2025 financial results before market open on Tuesday, March 31, 2026. Palvella management will host a conference call for investors at 8:30 a.m. ET on that same day to discuss the results and provide a corporate update. To access the live webcast

    3/24/26 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

    Primary endpoint met with statistically significant improvement (mean change of +2.13; p<0.001) on the Microcystic Lymphatic Malformation Investigator Global Assessment (mLM-IGA) Achieved statistical significance on pre-specified key secondary endpoint (p<0.001) and all four secondary efficacy endpoints (all p<0.001) 95% of trial participants aged ≥ 6 who completed the efficacy evaluation period improved on the mLM-IGA at Week 24 86% of trial participants aged ≥ 6 who completed the efficacy evaluation period were rated as "Much Improved" (+2) or "Very Much Improved" (+3) on the mLM-IGA at Week 24 QTORIN™ rapamycin was well-tolerated, with no drug-related serious adverse events reported a

    2/24/26 6:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics to Host Conference Call to Discuss Topline Results from Phase 3 SELVA Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) in Microcystic Lymphatic Malformations

    WAYNE, Pa., Feb. 23, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, today announced that it will host a conference call and webcast tomorrow, Tuesday, February 24, 2026, at 8:00am ET to discuss topline results from the Phase 3 SELVA clinical trial assessing the efficacy and safety of QTORIN™ 3.9% rapamycin anhydrous gel (QTORIN™ rapamycin) for the treatment of microcystic ly

    2/23/26 5:00:00 PM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Leadership Updates

    Live Leadership Updates

    View All

    Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

    Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (NASDAQ:ARQT), where he led U.S. sales efforts for ZORYVE®, a next-generation topical PDE4 inhibitor; previously, he held leadership roles at Incyte (NASDAQ:INCY) supporting the launch of OPZELURA® Mr. Taylor to lead Palvella's U.S. sales organization in preparation for the potential U.S. launch of QTORIN™ rapamycin for microcystic lymphatic malformations, a serious, rare, lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S. WAYNE, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Palvella Ther

    4/7/26 7:30:00 AM ET
    $ARQT
    $INCY
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

    Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (NASDAQ:KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth from FDA approval in 2023 to $389 million in annual sales in 2025 Ms. McDonough to lead Palvella's Market Access and Patient Services organizations, advancing payer engagement, patient support, specialty distribution, and access strategy for the Company's QTORIN™ programs targeting serious, rare skin diseases and vascular malformations WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or "the Company") (Nasdaq: PVLA), a clinical-stage biopharmaceut

    3/23/26 7:30:00 AM ET
    $KRYS
    $PVLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Palvella Therapeutics Strengthens Leadership Team with Appointment of Veteran Medical Affairs Leader Vimal Patel, PharmD, as Senior Vice President of Medical Affairs

    Seasoned dermatology and immunology executive brings more than 25 years of experience advancing and launching innovative therapies, including OPZELURA®, povorcitinib, ILUMYA®, ODOMZO®, REMICADE®, and STELARA® Dr. Patel to lead Palvella's Medical Affairs organization, advancing scientific engagement, KOL collaboration, disease state awareness, and medical education for the Company's QTORIN™ programs targeting serious, rare skin diseases, including microcystic lymphatic malformations and cutaneous venous malformations WAYNE, Pa., Jan. 07, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:PVLA) Palvella Therapeutics, Inc. (Palvella or "the Company"), a clinical-stage biopharmaceutical company focused on dev

    1/7/26 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PVLA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Palvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales

    Mr. Taylor brings a strong track record launching multiple high-profile therapies, most recently serving as Senior Vice President, Sales at Arcutis Biotherapeutics (NASDAQ:ARQT), where he led U.S. sales efforts for ZORYVE®, a next-generation topical PDE4 inhibitor; previously, he held leadership roles at Incyte (NASDAQ:INCY) supporting the launch of OPZELURA® Mr. Taylor to lead Palvella's U.S. sales organization in preparation for the potential U.S. launch of QTORIN™ rapamycin for microcystic lymphatic malformations, a serious, rare, lifelong genetic disease affecting an estimated more than 30,000 diagnosed patients in the U.S. WAYNE, Pa., April 07, 2026 (GLOBE NEWSWIRE) -- Palvella Ther

    4/7/26 7:30:00 AM ET
    $ARQT
    $INCY
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

    New Drug Application (NDA) for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations (microcystic LMs) on track for planned submission in second half of 2026 Accelerating U.S. launch readiness for QTORIN™ rapamycin for microcystic LMs; potential to become the first FDA-approved therapy and first-line, standard-of-care treatment for serious, lifelong disease affecting an estimated more than 30,000 diagnosed patients in the U.S. Initiation of Phase 3 trial of QTORIN™ rapamycin for the treatment of cutaneous venous malformations planned for second half of 2026 Initiation of Phase 2 trial of QTORIN™ rapamycin for the treatment of clinically significant angiokeratomas plan

    3/31/26 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Palvella Therapeutics Announces Scientific Publication in Journal of Vascular Anomalies Highlighting the Infiltrative Growth and Therapeutic Challenges of Microcystic Lymphatic Malformations

    Review delineates differences in clinical strategies between microcystic and macrocystic lymphatic malformations to guide disease-specific clinical trial design and treatment approaches Manuscript emphasizes the importance of early therapeutic intervention in children to help reduce the risk of more serious complications over time Review supports the scientific rationale of QTORIN™ 3.9% rapamycin anhydrous gel as a potential targeted therapy for microcystic lymphatic malformations WAYNE, Pa., March 30, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or "the Company") (NASDAQ:PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel

    3/30/26 7:30:00 AM ET
    $PVLA
    Biotechnology: Pharmaceutical Preparations
    Health Care